Actinium Pharmaceuticals, Inc. (ATNM) — 10-Q Filings

10-Q Filings (6)

• Actinium Narrows Q3 Loss by 56% on R&D, G&A Cuts — Nov 14, 2025 Risk: medium
  Actinium Pharmaceuticals, Inc. reported a net loss of $5.131 million for the three months ended September 30, 2025, a significant improvement from the $11.568 m
• Actinium Pharmaceuticals Reports No Revenue, Focuses on Iomab-B Phase 3 — Aug 8, 2025 Risk: high
  Actinium Pharmaceuticals, Inc. (ATNM) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a clinical-stage biopharmaceutical
• Actinium Pharmaceuticals Files Q1 2025 10-Q Report — May 9, 2025 Risk: low
  Actinium Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in Delaware, is in the pharmaceutical
• Actinium Pharmaceuticals Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Actinium Pharmaceuticals, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, is focused on pharmaceut
• Actinium Pharmaceuticals Files Q2 2024 10-Q — Aug 5, 2024 Risk: low
  Actinium Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, is based in N
• Actinium Pharmaceuticals Files Q1 2024 10-Q — Apr 26, 2024 Risk: low
  Actinium Pharmaceuticals, Inc. filed its quarterly report for the period ended March 31, 2024. The company is registered in Delaware and its common stock trades

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX